Evidence map›Paper›PMID 36376554›Full record

ArticleNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2023

Effects of monotherapy with a monoamine oxidase B inhibitor on motor symptoms in Parkinson's disease are dependent on frontal function.

Hidetomo Murakami, Motohiro Okumura, Masakazu Ozawa, Masahiro Mimori, Takahiro Maku, Tomotaka Shiraishi, Tomomichi Kitagawa, Hiroki Takatsu, Takeo Sato, Teppei Komatsu and 5 more

Abstract read
PubMed Publisher
In one paragraph

Article in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Catecholaminergic storm and extreme blood pressure lability induced by combined levodopa/benserazide, selegiline, and piribedil in Parkinson's disease: a case report.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Hidetomo MurakamiDepartment of Neurology, School of Medicine, The Jikei University, 3-25-8 Nishi-Shimbashi Minato-Ku 105-8461, Tokyo, Japan. hidneu@yahoo.co.jp.ORCID http://orcid.org/0000-0002-6551-4622
Motohiro OkumuraDepartment of Neurology, School of Medicine, The Jikei University, 3-25-8 Nishi-Shimbashi Minato-Ku 105-8461, Tokyo, Japan.
Masakazu OzawaDepartment of Neurology, School of Medicine, The Jikei University, 3-25-8 Nishi-Shimbashi Minato-Ku 105-8461, Tokyo, Japan.
Masahiro MimoriDepartment of Neurology, School of Medicine, The Jikei University, 3-25-8 Nishi-Shimbashi Minato-Ku 105-8461, Tokyo, Japan.
Takahiro MakuDepartment of Neurology, School of Medicine, The Jikei University, 3-25-8 Nishi-Shimbashi Minato-Ku 105-8461, Tokyo, Japan.
Tomotaka ShiraishiDepartment of Neurology, School of Medicine, The Jikei University, 3-25-8 Nishi-Shimbashi Minato-Ku 105-8461, Tokyo, Japan.
Tomomichi KitagawaDepartment of Neurology, School of Medicine, The Jikei University, 3-25-8 Nishi-Shimbashi Minato-Ku 105-8461, Tokyo, Japan.
Hiroki TakatsuDepartment of Neurology, School of Medicine, The Jikei University, 3-25-8 Nishi-Shimbashi Minato-Ku 105-8461, Tokyo, Japan.
Takeo SatoDepartment of Neurology, School of Medicine, The Jikei University, 3-25-8 Nishi-Shimbashi Minato-Ku 105-8461, Tokyo, Japan.
Teppei KomatsuDepartment of Neurology, School of Medicine, The Jikei University, 3-25-8 Nishi-Shimbashi Minato-Ku 105-8461, Tokyo, Japan.
Kenichiro SakaiDepartment of Neurology, School of Medicine, The Jikei University, 3-25-8 Nishi-Shimbashi Minato-Ku 105-8461, Tokyo, Japan.
Tadashi UmeharaDepartment of Neurology, School of Medicine, The Jikei University, 3-25-8 Nishi-Shimbashi Minato-Ku 105-8461, Tokyo, Japan.
Shusaku OmotoDepartment of Neurology, The Jikei University Katsushika Medical Center, 6-42-1 Aoto Katsushika-Ku 125-8506, Tokyo, Japan.
Hidetaka MitsumuraDepartment of Neurology, School of Medicine, The Jikei University, 3-25-8 Nishi-Shimbashi Minato-Ku 105-8461, Tokyo, Japan.
Yasuyuki IguchiDepartment of Neurology, School of Medicine, The Jikei University, 3-25-8 Nishi-Shimbashi Minato-Ku 105-8461, Tokyo, Japan.
Jikei University School of Medicine · JPKatsushika Medical Center · JP

Funding

Jikei University Research Fund Not availableMinistry of Education, Culture, Sports, Science, and Technology 21K03075
6 · The paper itself

Abstract

backgroundMonotherapy with monoamine oxidase B (MAO-B) inhibitors enhances the level of endogenous dopamine in treatment for Parkinson's disease (PD) and provides some benefits. Certain neuropsychiatric functions are also regulated by central dopaminergic activity.

aimTo investigate the relationship of the efficacy of monotherapy with MAO-B inhibitors on motor symptoms in PD with baseline cognitive function. PATIENTS AND

methodsOutcomes were examined for 27 consecutive drug-naïve PD patients who received initial treatment with a MAO-B inhibitor (selegiline: 11, rasagiline: 16). Selegiline was titrated to an optimal dose. The dose of rasagiline was fixed at 1 mg/day. Motor symptoms were assessed using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale part III before treatment and after the efficacy reached a plateau within 19 weeks after drug initiation, and the % improvement in motor symptoms was calculated. Pre-treatment cognitive function was assessed using the Montreal Cognitive Assessment (MoCA) and Frontal Assessment Battery (FAB). Correlations of % improvement in motor symptoms and baseline cognitive assessments were examined using Spearman correlation coefficients and multiple regression analysis.

resultsIn all patients, the mean % improvement in motor symptoms was 46.5% (range 0-83.3%). Spearman correlation coefficients showed the % improvement in motor symptoms was correlated with FAB (r = 0.631, p < 0.001). In multiple regression analysis with patient background factors as independent variables, only FAB was associated with improvement in motor symptoms in the MAO-B group.

conclusionBetter FAB scores predict a significant improvement in motor symptoms with treatment with MAO-B inhibitors, suggesting high activity of endogenous dopamine.

Indexed as

Parkinson DiseaseAntiparkinson AgentsDopamineDopamine AgentsHumansIndansMonoamine OxidaseMonoamine Oxidase InhibitorsSelegilineAntiparkinson AgentsDopamineDopamine AgentsIndansMonoamine OxidaseMonoamine Oxidase InhibitorsrasagilineSelegilineCognitive functionEndogenous dopamineExecutive functionFrontal Assessment BatteryMAO-B inhibitorParkinson’s disease

Identifiers

PMID36376554
OpenAlexW4308985804

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.